CSL announces Full-Year Results 2016-17

ASX announcement

16-August-2017 — CSL Limited announces 2016/17 Full Year Results for the period ending
30 June 2017. More.

CSL to acquire majority stake in
Chinese plasma fractionator ASX Announcement

13-June-2017 — The transaction will better serve patients with rare and serious diseases in this important high growth market... More.

Other recent news:

10-July-2017 — CSL Limited has become aware that Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the International Trade Commission. More.
23-June-2017 — CSL announced that the FDA has approved CSL Behring’s HAEGARDA®. More.
01-June-2017 — $1.25 Million Funding Available to Australia’s Best and Brightest Biomedical Researchers. More.

© 2017 CSL Limited